MTOR and breast cancer: Our analysis of the cellular responses to either GLS knockdown or pharmacological inhibition has identified potential PD markers and provides a molecular basis for combining GLS and mTOR inhibitors as a novel therapeutic strategy for treating basal breast cancers.